---
title: "HWHG: HW241045 tablets have received approval for clinical trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/251583894.md"
description: "According to the Zhitong Finance APP, HWHG announced that its wholly-owned subsidiary Wuhan Renfu Innovative Drug Research and Development Center Co., Ltd. recently received the \"Drug Clinical Trial Approval Notice\" for HW241045 tablets issued by the National Medical Products Administration. HW241045 tablets are suitable for the treatment of idiopathic pulmonary fibrosis, and currently, there are no drugs targeting the same site approved for marketing worldwide"
datetime: "2025-08-05T07:53:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/251583894.md)
  - [en](https://longbridge.com/en/news/251583894.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/251583894.md)
generator: "portal-rs"
---

# HWHG: HW241045 tablets have received approval for clinical trials

According to the Zhitong Finance APP, HWHG (600079.SH) announced that its wholly-owned subsidiary Wuhan Renfu Innovative Drug Research and Development Center Co., Ltd. recently received the "Drug Clinical Trial Approval Notice" for HW241045 tablets issued by the National Medical Products Administration. HW241045 tablets are suitable for the treatment of idiopathic pulmonary fibrosis, and currently, there are no drugs targeting the same site approved for marketing worldwide

### Related Stocks

- [600079.CN](https://longbridge.com/en/quote/600079.CN.md)

## Related News & Research

- [Humanwell unit Yichang Renfu wins China nod for labor pain trial of sufentanil injection](https://longbridge.com/en/news/295637927.md)
- [BREAKINGVIEWS-China's robots fail early market test](https://longbridge.com/en/news/297260520.md)
- [Canadian Solar Beats on Revenue, But Investors Face Softer Q3 Setup](https://longbridge.com/en/news/297210332.md)
- [WUXI APPTEC  Sells 4.23% Stake in WUXI XDC, Cashes In HKD3.9B](https://longbridge.com/en/news/297217460.md)
- [Robot brain builders are pushing out of their GPT-2 era](https://longbridge.com/en/news/297054926.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**